Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era

Takeda, Flávio Roberto; Ramos, Marcus Fernando Kodama Pertille; Pereira, Marina Alessandra; Muniz, Renan Rosetti; Tustumi, Francisco; Castria, Tiago Biachi De; Sallum, Rubens Antônio Aissar; Zilberstein, Bruno; Ribeiro, Ulysses; Cecconello, Ivan

doi:10.1016/j.amjsurg.2020.07.031

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lymphatic node metastases appear early in this disease, which is explained by the abundant lymphatic drainage in the esophageal submucosa. 19 Lymph node metastases in intramucosal adenocarcinomas (pT1a) vary between 0% and 15% in the literature. 20 , 21 In adenocarcinomas with submucosal infarction (pT1b), lymph node metastases are found in 4.1–50% of the cases.…”

Section: Discussionmentioning

confidence: 99%

Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study

Zhou

Chen

et al. 2021

Cancer Control

View full text Add to dashboard Cite

Background The number of patients diagnosed with T1 stage adenocarcinoma of esophagogastric junction (AEGJ) has been increasing. This study was conducted to investigate the effect of different treatment options (surgery, chemoradiation, and surgery+chemoradiation) on long-term survival in patients with T1-stage AEGJ. Methods We searched the Surveillance, Epidemiology, and End Results (SEER) database to identify the records of patients with T1-stage AEGJ between 2010 and 2018. Patient demographics and cancer parameters were compared among the three groups. The Kaplan–Meier method and Cox proportional hazard modeling were used to compare long-term survival. Results Data from 925 T1 stage AEGJ patients (surgery: n=516, surgery+chemoradiation: n=206, chemoradiation: n=203) were collected. We found that the OS and CSS rates of three treatment options had significant difference. Besides, positive nodal status also showed lower OS and CSS rat. Multivariate Cox regression analysis showed that surgery group has much lower risk of death compared with chemoradiation group and similar risk of death compared with surgery+chemoradiation group. Subgroup analysis suggested that in patients with N1–N3 status had higher OS and CSS rates in surgery+chemoradiation group. Conclusion Using SEER data, we identified a significant survival advantage with the use of surgery compared to chemoradiation in patients with T1-stage AEGJ while the long-term survival of patients after surgery+chemoradiation group was not significantly different and low risk of death in positive nodal status.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study

Zhou

Chen

et al. 2021

Cancer Control

View full text Add to dashboard Cite

show abstract

“…Most experts believe that AEG should be treated differently from gastric cancer and esophageal cancer, and multimodal treatment with surgical resection is considered the primary AEG treatment option [ 8 ]. Because of the high recurrence rate caused by invasion and metastasis, the prognosis of AEG patients is poor [ 9 ]. The TNM staging cannot adequately depict cancer prognosis because the survival rates of patients with the same TNM stage may be significantly different [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction

Zheng

Zhang

2022

Disease Markers

View full text Add to dashboard Cite

Adenocarcinoma of the esophagogastric junction (AEG) has increased rapidly worldwide during the last few decades. The purpose of this study is to investigate the clinical and prognostic characteristics of signal transduction and activator of transcription factor 3(STAT3) and phosphorylated STAT3 (p-STAT3) expression in AEG patients. We retrospectively analyzed the immunohistochemical results of 61 AEG patients and followed up for 5 years, while Western blot was performed on tissues from another 30 AEG patients. The results showed that STAT3 and p-STAT3 were overexpressed in AEG tissues ( P < 0.05 , P < 0.01 ). The high expression of STAT3 was significantly associated with the pTNM stage ( P < 0.05 ), and the increased expression of p-STAT3 was significantly associated with depth of invasion (pT), lymph node metastasis (pN), and pTNM stage ( P < 0.05 , P < 0.05 , P < 0.05 ). The 5-year survival rate for AEG patients was 41.0% and was significantly associated with tumor differentiation, pN, pTNM, and p-STAT3 ( P < 0.05 , P < 0.01 , P < 0.05 , P < 0.01 ). Cox regression analysis confirmed that tumor differentiation, pN, and high expression of p-STAT3 were independent risk factors for the 5-year survival rate in patients with AEG ( P < 0.05 , P < 0.01 , P < 0.05 ). Our study showed that STAT3 and p-STAT3 play a critical role in AEG development.

show abstract

Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era

Cited by 2 publications

References 15 publications

Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study

Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study

Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction

Contact Info

Product

Resources

About